Abstract: The present invention provides an antibody targeting an AXL protein or an antigen binding fragment thereof, and a preparation method therefor and use thereof. Further provided are an isolated polynucleotide encoding the antibody targeting the AXL protein or the antigen binding fragment thereof, and a vector comprising the isolated polynucleotide. The antibody targeting the AXL provided by the present invention can specifically bind to the AXL protein, can mediate ADCC to kill tumors, or have an anti-tumor effect as a target recognition domain of CART cells, and can be used for preventing or treating tumors, and hence it has a wide application prospect.

Abstract: Provided is an antibody capable of specifically binding to CD47or an antigen binding fragment thereof. Also provided is a recombinant oncolytic virus, which is operably inserted with or comprises a gene coding sequence of an anti-CD47antibody or a CD47ligand, wherein the anti-CD47antibody comprises an Fc mutant having A330L/I332E mutations (ALIE antibody), i.e., the anti-CD47antibody is ?CD47-Fc(ALIE). Also provided are a preparation method for the recombinant oncolytic virus, a use of the recombinant oncolytic virus in preparation of anti-tumor drugs, and a vaccinia virus Tiantan strain capable of efficiently expressing an ?CD47-Fc(ALIE) gene.

Abstract: The present invention provides a hypoxia-triggered artificial transcription factor (HATF), and further provides a hypoxia-triggered transcription control system. The transcription control system comprises a nucleic acid sequence encoding the HATF, and a recognition element (RE). The hypoxia-triggered transcription control system comprises two sets of transcription control units linked upstream and downstream, wherein the upstream transcription control unit comprises a hypoxia-triggered transcription reaction element for controlling the HATF and a nucleic acid sequence encoding the HATF, and the downstream transcription control unit comprises an RE and a gene of interest. Co-regulation by the artificial transcription factor HATF and the recognition element RE can increase the expression of the gene of interest by a factor of one hundred.

Abstract: A composition for inducing and/or amplifying TSCM in vitro, a culture medium including the composition, and a method for inducing and/or amplifying TSCM in vitro are provided, wherein the composition comprises inducing agents including IL-7 and IL-21. The chimeric antigen receptor T-memory stem cells induced differentiated and amplified by adding the composition can be used directly for reinfusion therapy of patients.